| CAF | Cancer-Associated Fibroblast |
| myCAF | Myofibroblastic Cancer-Associated Fibroblast |
| iCAF | Inflammatory Cancer-Associated Fibroblast |
| apCAF | Antigen-Presenting Cancer-Associated Fibroblast |
| meCAF | Metabolic Cancer-Associated Fibroblast |
| vCAF | Vascular Cancer-Associated Fibroblast |
| dCAF | Developmental Cancer-Associated Fibroblast |
| rCAF | Tumor-Restraining Cancer-Associated Fibroblast |
| pCAF | Tumor-Promoting Cancer-Associated Fibroblast |
| CSCs | Cancer Stem Cells |
| ECM | Extracellular Matrix |
| EMT | Epithelial-to-Mesenchymal Transition |
| EndMT | Endothelial-to-Mesenchymal Transition |
| TGF-β | Transforming Growth Factor Beta |
| IL-6 | Interleukin 6 |
| IL-10 | Interleukin 10 |
| CXCL12 | C-X-C Motif Chemokine Ligand 12 |
| CXCL1 | C-X-C Motif Chemokine Ligand 1 |
| CXCL16 | C-X-C Motif Chemokine Ligand 16 |
| JAK/STAT | Janus Kinase/Signal Transducer and Activator of Transcription |
| NF-κB | Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells |
| PDGF | Platelet-Derived Growth Factor |
| VEGF | Vascular Endothelial Growth Factor |
| WNT | Wingless/Integrated Signaling Pathway |
| HGF | Hepatocyte Growth Factor |
| IGF-1 | Insulin-Like Growth Factor 1 |
| PD-L1/PD-L2 | Programmed Death Ligand 1/2 |
| TLR4 | Toll-Like Receptor 4 |
| ATM | Ataxia Telangiectasia Mutated (signaling kinase) |
| IDO | Indoleamine 2,3-Dioxygenase |
| ARG2 | Arginase 2 |
| α-SMA | Alpha Smooth Muscle Actin |
| FAP | Fibroblast Activation Protein |
| CD4+ T cells | Cluster of Differentiation 4 Positive T Lymphocytes |
| CD8+ T cells | Cluster of Differentiation 8 Positive T Lymphocytes |
| Tregs | Regulatory T Cells |
| TAMs | Tumor-Associated Macrophages |
| MDSCs | Myeloid-Derived Suppressor Cells |
| MHC | Major Histocompatibility Complex |
| TLS | Tertiary Lymphoid Structures |
| DCN | Decorin |
| CTHRC1 | Collagen Triple Helix Repeat Containing 1 |
| CD63 | Cluster of Differentiation 63 |
| CD10 | Cluster of Differentiation 10 |
| PDGFR | Platelet-Derived Growth Factor Receptor |
| SDF-1 | Stromal-Derived Factor 1 |
| CXCR4 | C-X-C Chemokine Receptor Type 4 |
| scRNA-seq | Single-Cell RNA Sequencing |
| TME | Tumor Microenvironment |
| TIME | Tumor Immune Microenvironment |
| 3D | Three-Dimensional |
| EVs | Extracellular Vesicles |
| PDAC | Pancreatic Ductal Adenocarcinoma |
| NSCLC | Non-Small Cell Lung Cancer |
| HCC | Hepatocellular Carcinoma |
| RMS | Rhabdomyosarcoma |
| UPS | Undifferentiated Pleomorphic Sarcoma |
| STS | Soft Tissue Sarcoma |
| EwS | Ewing Sarcoma |
| HNSCC | Head and Neck Squamous Cell Carcinoma |
| NETs | Neuroendocrine Tumors |
| MHC-II | Major Histocompatibility Complex Class II |
| ZEB1 | Zinc Finger E-Box Binding Homeobox 1 |
| TBX2 | T-Box Transcription Factor 2 |
| SOX9 | SRY-Box Transcription Factor 9 |
| COL6A1 | Collagen Type VI Alpha 1 Chain |
| HJURP | Holliday Junction Recognition Protein |
| MCM2 | Minichromosome Maintenance Complex Component 2 |
| ANXA2 | Annexin A2 |
| AR | Androgen Receptor |
| CXCL14 | C-X-C Motif Chemokine Ligand 14 |
| ABCB1 | ATP-Binding Cassette Sub-Family B Member 1 |
| ABCC2 | ATP-Binding Cassette Sub-Family C Member 2 |
| MRP1 | Multidrug Resistance-Associated Protein 1 |
| miRNA/miR | MicroRNA, e.g., miR-105, miR-21, miR-146a, miR-1228, miR-4717-5p |
| lncRNA | Long Non-Coding RNA, e.g., ANRIL, LINC00355 |
| ICB | Immune Checkpoint Blockade |
| CAR-T | Chimeric Antigen Receptor T-Cell Therapy |
| TKIs | Tyrosine Kinase Inhibitors |
| ADC | Antibody–Drug Conjugate |
| MMAE | Monomethyl Auristatin E |
| OXPHOS | Oxidative Phosphorylation |
| TCA Cycle | Tricarboxylic Acid Cycle (Krebs Cycle) |